0001209191-21-033362.txt : 20210517 0001209191-21-033362.hdr.sgml : 20210517 20210517215701 ACCESSION NUMBER: 0001209191-21-033362 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210515 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chowdhury Badrul A. CENTRAL INDEX KEY: 0001776662 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 21933587 MAIL ADDRESS: STREET 1: PROTEOSTASIS THERAPEUTICS, INC. STREET 2: 80 GUEST STREET, SUITE 500 CITY: BOSTON STATE: MA ZIP: 02135 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 512-614-1848 MAIL ADDRESS: STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY STREET 2: SUITE 150 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-15 0 0001160308 Savara Inc SVRA 0001776662 Chowdhury Badrul A. 6836 BEE CAVE ROAD BUILDING III, SUITE 200 AUSTIN TX 78746 0 1 0 0 CHIEF MEDICAL OFFICER Common Stock 2021-05-15 4 M 0 200000 0.00 A 200000 D Common Stock 2021-05-17 4 S 0 50000 1.5574 D 150000 D Restricted Stock Units 0.00 2021-05-15 4 M 0 200000 0.00 D Common Stock 200000 0 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020 in order to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 15, 2021. The price is a weighted average sale price. The sale prices ranged from $1.50 to $1.61. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. The restricted stock units vested in full on May 15, 2021. /s/ David Lowrance as attorney-in-fact for Badrul Chowdhury 2021-05-17